BIOMAT Database Logo BIOMAT Database Logo

Prognostic implication of labeling index versus estrogen receptors and tumor size in node-negative breast cancer. 1986

R Silvestrini, and M G Daidone, and G Di Fronzo, and A Morabito, and P Valagussa, and G Bonadonna

The paper analyzes the relation among tumor size (T), estrogen receptor (ER) status, and labeling index (LI) and their relative merits in predicting the relapse-free (RFS) and overall survival (OS) in 215 node-negative women with primary breast cancer. All patients were subjected to Halsted or modified radical mastectomy; none received postoperative irradiation or systemic adjuvant therapy. The 5-year RFS was 75.3% and OS 89.0%. When singly tested, LI and ER were able to significantly predict RFS and OS. In contrast, T influenced only RFS but not OS. The multivariate analysis showed that, in the presence of the two other variables, only LI retained its prognostic significance both for time to relapse (p = 0.0044) and survival (p = 0.035). From the present findings, LI appears to be a new important prognostic variable in the selection of high risk patients for whom adjuvant systemic therapy should perhaps be part of their primary treatment.

UI MeSH Term Description Entries
D008198 Lymph Nodes They are oval or bean shaped bodies (1 - 30 mm in diameter) located along the lymphatic system. Lymph Node,Node, Lymph,Nodes, Lymph
D008408 Mastectomy Surgical procedure to remove one or both breasts. Mammectomy,Mammectomies,Mastectomies
D008593 Menopause The last menstrual period. Permanent cessation of menses (MENSTRUATION) is usually defined after 6 to 12 months of AMENORRHEA in a woman over 45 years of age. In the United States, menopause generally occurs in women between 48 and 55 years of age. Change of Life, Female
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009367 Neoplasm Staging Methods which attempt to express in replicable terms the extent of the neoplasm in the patient. Cancer Staging,Staging, Neoplasm,Tumor Staging,TNM Classification,TNM Staging,TNM Staging System,Classification, TNM,Classifications, TNM,Staging System, TNM,Staging Systems, TNM,Staging, Cancer,Staging, TNM,Staging, Tumor,System, TNM Staging,Systems, TNM Staging,TNM Classifications,TNM Staging Systems
D011237 Predictive Value of Tests In screening and diagnostic tests, the probability that a person with a positive test is a true positive (i.e., has the disease), is referred to as the predictive value of a positive test; whereas, the predictive value of a negative test is the probability that the person with a negative test does not have the disease. Predictive value is related to the sensitivity and specificity of the test. Negative Predictive Value,Positive Predictive Value,Predictive Value Of Test,Predictive Values Of Tests,Negative Predictive Values,Positive Predictive Values,Predictive Value, Negative,Predictive Value, Positive
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D011868 Radioisotopes Isotopes that exhibit radioactivity and undergo radioactive decay. (From Grant & Hackh's Chemical Dictionary, 5th ed & McGraw-Hill Dictionary of Scientific and Technical Terms, 4th ed) Daughter Isotope,Daughter Nuclide,Radioactive Isotope,Radioactive Isotopes,Radiogenic Isotope,Radioisotope,Radionuclide,Radionuclides,Daughter Nuclides,Daugter Isotopes,Radiogenic Isotopes,Isotope, Daughter,Isotope, Radioactive,Isotope, Radiogenic,Isotopes, Daugter,Isotopes, Radioactive,Isotopes, Radiogenic,Nuclide, Daughter,Nuclides, Daughter
D011960 Receptors, Estrogen Cytoplasmic proteins that bind estrogens and migrate to the nucleus where they regulate DNA transcription. Evaluation of the state of estrogen receptors in breast cancer patients has become clinically important. Estrogen Receptor,Estrogen Receptors,Estrogen Nuclear Receptor,Estrogen Receptor Type I,Estrogen Receptor Type II,Estrogen Receptors Type I,Estrogen Receptors Type II,Receptor, Estrogen Nuclear,Receptors, Estrogen, Type I,Receptors, Estrogen, Type II,Nuclear Receptor, Estrogen,Receptor, Estrogen
D001943 Breast Neoplasms Tumors or cancer of the human BREAST. Breast Cancer,Breast Tumors,Cancer of Breast,Breast Carcinoma,Cancer of the Breast,Human Mammary Carcinoma,Malignant Neoplasm of Breast,Malignant Tumor of Breast,Mammary Cancer,Mammary Carcinoma, Human,Mammary Neoplasm, Human,Mammary Neoplasms, Human,Neoplasms, Breast,Tumors, Breast,Breast Carcinomas,Breast Malignant Neoplasm,Breast Malignant Neoplasms,Breast Malignant Tumor,Breast Malignant Tumors,Breast Neoplasm,Breast Tumor,Cancer, Breast,Cancer, Mammary,Cancers, Mammary,Carcinoma, Breast,Carcinoma, Human Mammary,Carcinomas, Breast,Carcinomas, Human Mammary,Human Mammary Carcinomas,Human Mammary Neoplasm,Human Mammary Neoplasms,Mammary Cancers,Mammary Carcinomas, Human,Neoplasm, Breast,Neoplasm, Human Mammary,Neoplasms, Human Mammary,Tumor, Breast

Related Publications

R Silvestrini, and M G Daidone, and G Di Fronzo, and A Morabito, and P Valagussa, and G Bonadonna
Prognostic value of Ki-67 labeling index in patients with node-negative, triple-negative breast cancer.
July 2012, Breast cancer research and treatment,
R Silvestrini, and M G Daidone, and G Di Fronzo, and A Morabito, and P Valagussa, and G Bonadonna
Node-negative breast cancer: prognostic subgroups defined by tumor size and flow cytometry.
December 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
R Silvestrini, and M G Daidone, and G Di Fronzo, and A Morabito, and P Valagussa, and G Bonadonna
Estrogen receptor versus nuclear grade as prognostic factors in axillary node negative breast cancer.
July 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
R Silvestrini, and M G Daidone, and G Di Fronzo, and A Morabito, and P Valagussa, and G Bonadonna
Prognostic Significance of Progesterone Receptor Expression in Estrogen-Receptor Positive, HER2-Negative, Node-Negative Invasive Breast Cancer With a Low Ki-67 Labeling Index.
February 2017, Clinical breast cancer,
R Silvestrini, and M G Daidone, and G Di Fronzo, and A Morabito, and P Valagussa, and G Bonadonna
A prognostic index for operable, node-negative breast cancer.
May 2004, British journal of cancer,
R Silvestrini, and M G Daidone, and G Di Fronzo, and A Morabito, and P Valagussa, and G Bonadonna
Labeling of estrogen receptors in breast cancer.
January 1986, International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology,
R Silvestrini, and M G Daidone, and G Di Fronzo, and A Morabito, and P Valagussa, and G Bonadonna
Prognostic relevance of immunohistology, tumor size and vascular space involvement in axillary node negative breast cancer.
January 1998, Archives of gynecology and obstetrics,
R Silvestrini, and M G Daidone, and G Di Fronzo, and A Morabito, and P Valagussa, and G Bonadonna
Prognostic relevance of cathepsin D versus oestrogen receptors in node negative breast cancers.
January 1991, European journal of cancer (Oxford, England : 1990),
R Silvestrini, and M G Daidone, and G Di Fronzo, and A Morabito, and P Valagussa, and G Bonadonna
The effect of tumor size and axillary lymph node metastasis on estrogen and progesterone receptors in primary breast cancer.
March 1986, Journal of surgical oncology,
R Silvestrini, and M G Daidone, and G Di Fronzo, and A Morabito, and P Valagussa, and G Bonadonna
The DNA labelling index: a prognostic factor in node-negative breast cancer.
January 1987, Breast cancer research and treatment,
Copied contents to your clipboard!